Around two in three heart failure patients do not receive the recommended treatment following hospitalisation, according to new research.
The use of aldosterone antagonist therapy has been recommended by the American Heart Association, because it opposes the action of adrenal hormone aldosterone.
However, only 28.8 per cent of the 43,625 patients admitted to hospital for heart failure were given the treatment, according to researchers from the Cleveland Clinic.
The researchers also took into account temporal trends and appropriateness of use, which can be a determining factor in the administration of the treatment.
Authors wrote: "Given the substantial morbidity and mortality risk faced by patients hospitalized with HF [heart failure] and the established efficacy of aldosterone antagonist prescription in HF, a stronger uptake of aldosterone antagonist therapy indicated by evidence-based guidelines may be warranted."
Meanwhile, research published in the October 21st issue of Jama indicated that the use of omega-3 as a treatment for depression in heart disease may not provide benefit.
Please click here for advice to help you find the right type of care.